Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026)

Forte Biosciences (FBRX) has reported Free Cash Flow for 11 consecutive years, with -$18.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 80.49% year-over-year to -$18.8 million; the TTM figure through Mar 2026 stood at -$59.4 million (down 72.05% YoY), while the FY2025 annual figure was -$51.0 million, down 65.73% from the prior year.
• Free Cash Flow slipped to -$18.8 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$1.4 million in Q2 2022 and bottomed at -$18.8 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$8.1 million across 5 years, with a median of -$8.1 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 65.03% — and 2023, when it slumped 369.02%.
• Forte Biosciences' Free Cash Flow stood at -$2.9 million in 2022, then plunged by 210.61% to -$9.0 million in 2023, then slipped by 11.73% to -$10.0 million in 2024, then tumbled by 64.18% to -$16.5 million in 2025, then dropped by 14.05% to -$18.8 million in 2026.
• Business Quant data shows FBRX's Free Cash Flow at -$18.8 million in Q1 2026, -$16.5 million in Q4 2025, and -$14.1 million in Q3 2025.